Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Share price up about 5.14% with increased volume based on the above information.

Interesting to see next week.

Will this ever be a quid again?

Seriously, they seem to bring out a stream of decent news. You'd think it would stick more than the smellier stuff these days. Hmm.

BA, I think so, but it has to breakout of the present side way trading and break through its 75p resistance level.

The projected results should support future higher price.

The majority of analyst are positive.

I think (hope) it will fly over the next few months unless stalled by overall market retracement.

Sentiment is a strong driver in stock markets unfortunately Fred.

It seems to be bad around here still.

You don't think they may takeover SEO again. 8-)

News Article
Acquisition of PharmaHerb Limited
21/05/2007


London, UK, 21 May 2007: BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company today announces the acquisition of PharmaHerb Limited ("PharmaHerb), a UK-based vitamin and nutritional business. The consideration for the acquisition was 600,000 which has been settled by 150,000 cash and the issue of 694,981 ordinary shares of the Company with a value of 450,000. Application will be made for these new ordinary shares to be admitted to trading on the AIM market of the London Stock Exchange. It is expected that dealings will commence on 24 May 2007.


PharmaHerb is a specialist 'Over-the-Counter' (OTC) products company, whose core activities include product formulation, manufacturing and packaging. The acquisition includes PharmaHerb"s Kudos range of brands together with its sales and marketing capabilities. The Kudos brand is a premier label business focused on the promotion of vitamin and nutritional products through established and diversified distribution channels. These distribution channels include niche health shops, pharmacies as well as supermarket chains. The business also has a direct-to-consumer internet sales capability (www.kudosvitamins.com).

The acquisition of PharmaHerb creates an OTC platform for the Company with established sales and marketing channels which will allow BioProgress to directly market its own OTC ranges into its domestic market. Pharmaherb acquired the assets of Kudos in March 2007 which included packaging equipment, stock, formulations, intellectual property as well as sales and marketing agreements and established channels to the OTC consumer market. The sales of Pharmaherb are negligible (2006 sales of Kudos were 255,000 and the business invested approximately 1m in capital for assets and infrastructure growth), however, the assets represent an operating infrastructure and thus a low cost entry into the UK market. BioProgress expects to utilise these assets immediately to create strong organic growth. Combining the Kudos and Dexo product ranges will provide a broader product portfolio to further develop and expand the acquired sales and distribution capabilities. In particular the business will be used as a base to launch future UK Soluleaves, Meltums and other XGEL enhanced OTC products.

The acquisition is analogus to that of DMPL earlier in the year and will provide a significant distribution channel for the MINCI DIET product range as well as supporting the co-promotion of SlimThru obtained through a partnership agreement with Melbrosin International, announced earlier this year.

Richard Trevillion, Chief Executive Officer said:

The acquisition of PharmaHerb Limited and the Kudos brand are an important step as a launch pad for our own XGEL OTC products and to generate revenues within the UK market place. The acquisition further strengthens our position and reflects our drive into the growing niche branded OTC market. The established distribution channels that come with this acquisition allows us greater and more rapid market access for our growing product portfolio.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO


Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

How times change. 3 years ago this was the stepping stone to world domination. It brings a wry smile to one's face. ;-))



BioProgress PLC
29 May 2007


For Immediate Release 29 May 2007


BioProgress plc ('BioProgress' or the 'Company')
Intention to delist from NASDAQ, deregister and terminate SEC reporting
obligations

London, UK, (29 May 2007): BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty
pharma and healthcare company today announces that it will delist its Amercian
Depositary Receipts ('ADRs') from The NASDAQ Stock Market and deregister and
terminate the Company's reporting obligations under the U.S. Securities Exchange
Act of 1934 (the 'Exchange Act'). The Company's Ordinary Shares will continue to
trade on London's AIM.

The Company has provided written notice to NASDAQ of its intention to delist and
intends to file a Form 25 with the SEC on 8 June 2007 to effect the delisting.
The Company reserves the right to delay the filing of the Form 25 or withdraw
the Form 25 for any reason prior to its effectiveness. The delisting is expected
to take effect on 18 June 2007 at which point the Company will file a Form 15F
with the SEC to deregister and terminate its reporting obligations under the
Exchange Act. The deregistration is expected to become effective on 17 September
2007, by operation of law. The Company reserves the right to delay the filing of
the Form 15F or withdraw the Form 15F for any reason prior to its effectiveness.

The decision to delist from NASDAQ, deregister and terminate the Company's
reporting obligations under the Exchange Act has been made due to the burdensome
costs of compliance with the SEC rules and in particular the Section 404
requirements of the Sarbanes-Oxley Act of 2002. The Company believes that the
cost of compliance outweighs the limited benefits and trading in the company's
shares for a company like BioProgress and the cash saved can be put to greater
use in other parts of the business.

The Company expects to maintain its ADR facility with JPMorgan Chase Bank, N.A.,
and to amend its Deposit Agreement with JPMorgan Chase Bank, N.A., to reflect
its deregistration and allow its ADR's to trade on the over-the-counter (OTC)
market in the United States. BioProgress expects to continue to publish its
Results and other documents and communications in accordance with Exchange Act
Rule 12g3-2 on its Web site, located at www.bioprogress.com.

Richard Trevillion, Chief Executive Officer commented:
'At this stage of the Company's development there are limited benefits of a dual
listing and the costs of maintaining the NASDAQ listing have increased
significantly over the last 18 months. The cost savings can be utilised to
accelerate the growth of the business, particularly in the United States, which
continues to be an important market for the business.'

For further information:

BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court

Just to keep Dil happy, but it is an impressive list.

LSE 61.66 p +2.41
Nasdaq 11.61 $ 0.00Latest News News Alert Downloads Media Relations About Us Pharma Product Development Enabling Systems Production Investor Relations Media Relations Contact Us Home> Media> Latest News> ArticleNews Article
Proprietary Product Development Update
31/05/2007



London, UK, 31 May 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, today announces an update on its product development program.


BioProgress has nine integrated enabling drug delivery technologies with pharmaceutical and healthcare applications. The Company has in development over 30 patent protected products using these core enabling technologies. The developments are classed into three main categories

1. OTC and Nutritional Products

2. Line extensions for acquired Pharmaceutical Brands

3. Innovative Products suitable for out-licensing or for sale by Dexo BioPharm

1. OTC and Nutritional Products

The Company has launched a range of Soluleaves nutritional products in the United States and Europe. In addition, in the OTC pharmaceutical sector, the Company has developed a range of Soluleaves products for launch initially through Dexo US. The products include respiratory drugs, cough / cold and sore throat products. These products do not require pre-FDA approval and will be marketed throughout 2007. Development work is carried out at the Company's facilities in Cambridge, UK and in Tampa, USA. The range includes the following:



Technology Development Phase

DBP130 Anti-Diarrhoea Soluleaves Pre-registration
DBP147 Local Anaesthetic Soluleaves Launch phase - US
DBP211 Decongestant Soluleaves Pre-registration
DBP214 Anti-histamine Soluleaves Pre-registration
DBP216 Analgesic TabWrap Scale Up
DBP310 Analgesic - basic FastWrap Pre-registration
DBP312 Analgesic - combination FastWrap Pre-registration
DBP314 Analgesic Cold & flu FastWrap Pre-registration


The Global OTC market for analgesics and cough/cold products is worth $16.7 Billion per annum. Similar new novel patented pharmaceutical technologies can achieve sales penetration rates of approximately one percent of the relevant market share.

2. Line Extensions for acquired Pharmaceutical Brands

BioProgress has acquired a number of branded medicines suitable for immediate extension utilizing one of the Company"s enabling systems. The main developments in this area are:

Product Territory Launch

DBP213 Cough Ah-Chew extension USA 2007
DBP215 Cough & Cold Ah-Chew extension USA 2007
DBP272 Gastric Reflux -Combo RocGe EU 2008
DBP274 Gastric Reflux - Basic RocGel Global 2008/9
DBP276 Gastric Reflux - Chewable RocGel Global 2008/9


The Ah-Chew line extensions use Soluleaves technology and will be the first oral thin film within the US DESI prescription market. The line extensions for RocGel use the liquid SoluPol technology, as well as a chewable tablet, and are expected to be a core driver for pan-European sales within the gastro-intestinal market. The SoluPol range of products has been developed by the Cambridge Development team.

3. Key Innovative Developments

The Companys core new development includes the following:-

DBP117 Anti-Migraine

The Development team has been able to overcome significant technical challenges to place an anti-migraine drug of a class of compound known as a triptan into an oral film strip. The triptan market includes brands such as Imitrex (GSK) and Zomig (AstraZeneca) and is worth $3.1 billion in 2007 (Datamonitor) growing at 3.1% per annum. A number of these products are converting from Prescription to Over the Counter use which is expected to expand the market.

The product has passed the initial formulation phase and is due to commence scale-up manufacturing trials in H2 2007. The product is planned for submission to US and EU regulatory authorities during 2008. It is expected that DBP117 will achieve peak sales revenues of 1 to 1.5 percent of the Global triptan market share per annum.

DBP118 Anti-emesis

BioProgress has developed a product for anti-emesis which has been induced by cancer therapy. The category of medicines is called 5-HT3 antagonists, such as Zofran (GSK) and Kytril (Roche), have become the mainstay of the treatment of oncology induced nausea.

The Company has formulated a DBP118 using the Oradisc technology, owned by Uluru Inc. The product uses a buccal disc that can dissolve gradually over time, allowing for the sustained release of the active drug.

It is expected that the product will enter into pharmacokinetic studies during 2008 with the product being filed using the NDA 505 (b) (2) regulatory pathway. The Company is expecting peak sales revenues to be in the region of $32-40m per annum.

DBP121 Smoking Cessation Product

BioProgress has developed a new concept in smoking cessation. Whilst lozenges and microtabs take 10-30 minutes to deliver their nicotine content, a cigarette typically will deliver the effects of its nicotine in seconds. Current therapies do not mimic this "high and therefore smokers find it difficult to reduce the number of cigarettes accordingly. The current global smoking cessation market is estimated to be $2.3 billion (Datamonitor)

The Company completed its first volunteer study in April 2007 as an open assessment study in volunteer smokers. This study showed a marked decrease in cravings using DBP121. Along with positive taste and consumer acceptability information, this data has been instrumental in the Companys discussions with several global partners. BioProgress is currently assessing all of the potential partners from global to regional partners in order to extract the maximum benefit for the Company.

From detailed market analyses and from other launches of new nicotine replacement dosage forms, BioProgress anticipates that DBP121has a peak sales potential of $150 to 200m per annum within the smoking cessation market.

DBP167 Analgesic

DBP167 is a series of developments using a novel form of ibuprofen in conjunction with polymer technology. The development is focusing on the requirement to deliver analgesia significantly quicker into the blood stream than traditional pharmaceutical tablets. Published data shows that standard paracetamol type of analgesics can take 40-90 minutes before the patient is able to see a noticeable reduction in pain. BioProgresss product has demonstrated impact in only a few minutes, anything from a simple headache, migraine or breakthrough pain can be effectively and quickly treated.

SoluPol liquids, Meltums (melt in the mouth), NRobe and FastWrap versions are all scheduled for development as analgesic indications along with a novel sachet formulation integrating decongestants for line extensions into the Ah-Chew franchise.

The global OTC market for analgesics alone is currently $6.2 billion with the cough-cold market being $10.5 billion. With the addition of the prescription analgesic market, BioProgress believes that it has a unique marketing advantage over the main competitors. The products will be promoted into the prescription market as well as the OTC market and will become a cornerstone of the BioProgress core product developments.

DBP167 will enter regulatory submission in H2 2007, with the further developments progressing through formulation and scale-up.

With the target OTC market being in excess of $16 billion, the company estimates that its innovative prescription and OTC strategy would lead to a 1 - 1.5 % market share of the major pharmaceutical markets.

Steve Martin, Chief Development Officer said:

BioProgress has made significant progress over the last year converting its enabling technologies into tangible product developments that meet consumer and partner expectations. We have launched three new technologies, EntWrap, FastWrap and Meltums. Each of these technologies has been well received by potential partners and as the Company has progressed in its developments, the data accumulated has been instrumental in increasing the partner interest.

The Development team is working on a number of confidential product projects with other pharmaceutical companies using the full range of enabling technologies. With revenues currently being received from its restructured NRobe technology licence agreement, the Company is in a strong position to deliver its own technologies to the consumer market.

Product launches are scheduled throughout 2007 and beyond, a healthy pipeline is essential for the future growth and profitability of BioProgress. The Development Team has worked tirelessly to create our vision of medicines that act quickly and are easy to take.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO


Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Companys filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.










Privacy Statement | Disclaimer | Trade Mark Statement | Accessibility Statement | Sitemap | Glossary

Ta Fred ... much appreciated :-)

Yeah, right. ;-))

:-)

Just for the mafiosa, Dil and Big AL


May help the price a little. At least profit looks on its way.


Home Log Out Upgrade Our Services My Account Contact Help



Stockwatch Level 2 Portfolio Charts Shares Magazine Research Quote Indices Market Scan Company Zone Traders' Room
NewsWatch Trades Terminal Alerts Stock Screener Heatmaps News Mobile Futures CompanyAV Investors' Room
World Markets Webcast Directory Bookshop Personal Finance Mortgages Forex Loans Credit Cards Simply Chart ISAs








BioProgress PLC
06 June 2007


For Immediate Release 6 June 2007



BioProgress launch first SoluleavesTM products in UK



London, UK, 5th June 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company,
is pleased to announce the launch in the UK of the first of its range of
SoluleavesTM, melt in the mouth products.



The first two SoluleavesTM products to be marketed will be, Caffeine Soluleaves
TM - energy boost, and Zinc and Echinacea, which helps boost natural defences
against colds and flu. Other SoluleavesTM products including Vitamin B complex
and anti-snoring will be launched in the coming weeks.



The SoluleavesTM range of products will be marketed through the newly acquired
PharmaHerb Limited, a specialist Over The Counter (OTC) products company, using
the Kudos brand. Distribution will be through its established niche health
shops, pharmacies, supermarket chains, as well as its direct to consumer
internet selling (
www.kudosvitamins.com
).



The market for energy products in the UK is valued around 700m, with the UK
cough cold market valued at 430m. The company believes the products possess a
number of advantages over existing market products such as being quick to
disperse in the mouth leading to rapid onset of action, and suitable for people
who have difficulty swallowing tablets and capsules. Peak sales are estimated to
be within 1 to 1.5% of their appropriate market.



Richard Trevillion, Chief Executive Officer, of BioProgress commented:

'It is testament to the strength and depth of the Company's infrastructure that
BioProgress has been able to reformulate to UK standards and launch new products
in record time. This launch has been timed to capitalize upon the recent
acquisition of PharmaHerb. It will also be the first time consumers will have
access to the benefits of the SoluleavesTM system in the UK market'.











For further information:


BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court





About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGELTM polymer technology, replacing the need to
use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to
www.bioprogress.com




Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.












This information is provided by RNS
The company news service from the London Stock Exchange





| Register | Our Services | About MoneyAM | Terms and Conditions | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us |
2006 MoneyAM

And another. why can't SEO do the same.


News Article
News Flash: SlimThru Update
06/06/2007


BioProgress and Melbrosin have been working together on the television support of the unique food and weight management brand, SlimThru which has achieved excellent results.



The UK TV campaign breaking across terrestrial and satellite channels throughout June 2007 for a period of six weeks forms part of a wider marketing campaign including a radio campaign, press promotions and PR. This directs people to the www.slimthru.co.uk website which achieved a record of almost 10,123 contacts in the first 5 days of advertising.



SlimThru has been successfully launched in a number of EU countries under various related brand names and has achieved market leadership in Austria in the first 5 weeks of marketing. Similar successes are being achieved in other markets.



BioProgress PLC will continue to work as co-promotion partner with Melbrosin using its developing network of retail outlets and supporting the media campaign.

Not much of a reaction there. I'm still surprised all this good news has no effect whatsoever.

Shame for holders I guess.

I have a feeling more and more are realising that the smaller companies with large R and D costs, promises for tomorrow, with little cash flow have a disproportionate risk. Also in BPRG share price has been a heltershelter ride for years.

Another factor is sentiment to the market at the moment, my guess for the last few days the flow of cash was out of the market in general. The same information in a more bullish market would have lifted it.

BPRG promises profit for this year, a change and future projections are promising. The market they are catering for is substantial and sustainable.
I would consider it a good defensive stock.
I think the outlook is good. But DYOH.

If you are holding still this may cheer your hearts.



Also worth a look at projected earnings.



It is up 7.1% on last nights close.


I think this is one for the future, but check its PE against your toleration.

I have held on and off for years.



News Article

AGM Statement and Company Update
19/06/2007

BioProgress plc ('BioProgress' or the 'Company')

AGM Statement and Company Update

London, UK, 19 June 2007: BioProgress (AIM: BPRG), the speciality pharma and healthcare company, is holding its AGM at 2.30pm today and will make the following update.

Trading

The Company is pleased to announce that it is trading above annualised turnover expectations for the half year to June 2007. Its current sales and marketing operations, are performing to expectations and benefiting from increased market awareness due to several recent product launches. With the product portfolio currently focused upon seasonal products with peak sales expected from September and with the additional acquisition of Rocgel, BioProgress is confident that the progress made through the first half of the year will be maintained through the second half of the year.

Partners

BioProgress is also pleased to announce a new commercial relationship with Merck-Serono, one of the largest pharmaceutical companies in the world. The Company is partnering four of its developed and commercialised technologies with a division of Merck-Serono, comprising TabWrap, FastWrap, SoluPoland Meltums for products specifically in the area of female healthcare, a global $54 billion market. The Company is also working with an additional three global pharmaceutical companies all with multiple enabling systems. In addition, the Company is currently in detailed product and technology discussions with over 15 different pharmaceutical companies for commercial partnering arrangements. The technology focus of these developments are related to the TabWrap, FastWrap, Soluleaves and SoluPol enabling systems. The product indications are focussed within the analgesic, cough/cold and gastro-intestinal categories. The developments with partners include the use of the technology with category leading brands within the US and other markets.

BioProgress will receive milestone, royalty and licensing payments along with development and co-commercialisation rights. Some of the partner programs incorporate profit-sharing agreements. The Company is expecting an increase in the number of new partner development programs during the second half of 2007. The Company will also maintain manufacturing rights for certain of these arrangements.

The Global OTC analgesic market is worth $6.2 billion in 2007 (Datamonitor) with the US, UK and Japan being the largest three single national markets. This market centres around paracetamol/acetaminophen, ibuprofen and aspirin as the major molecules. The global OTC cough/cold market is worth $10.5 billion with the USA, Japan and Germany being the three largest national markets.

In addition, the Company has identified its preferred partner for its smoking cessation product, DBP121. The marketing aspects of the partnering program are currently being assessed on a global basis with BioProgress retaining certain rights to some territories and the manufacturing rights. The global market size is $2.1 billion within the OTC arena with the US having an additional $300m for prescription only products.

Products

BioProgress is also pleased to announce that it is launching a new topical treatment for the treatment of cellulite. Using natural remedies and caffeine, the hypoallergenic gel uses BioProgress' patented technology to act as drug penetration enhancer for molecules across the skin. The market is significant with over 10% of all women in France using a topical treatment for cellulite and body toning.

The product has been shown to deliver the active ingredients over twice as effectively as the leading brand products. The topical treatment will be marketed as Kudos Anti-cellulite Cream and will form an integral marketing strategy with the Slimthru brand. The Company"s co-promotion partner, Melbrosin International, will be launching the product within the Austrian and German markets. The anti-cellulite creams market is worth more than $30m in the UK alone. The global cosmetics market was valued by Euromonitor at $253.6bn in 2005, up 8.2% on 2004. The technology has a number of other advantages and is currently being investigated for the area of burns associated with radiotherapy.

Technologies

In parallel with the above significant and exciting developments, the Company is pleased to announce that its TabWrap enabling system, together with its derivatives EntWrap and FastWrap, are now in commercial scale-up and validation. The final system, housed in a fully compliant CGMP facility, will be shown at the AGM.

The Company is also pleased to announce the successful development of a new generation of XGEL films for the TabWrap machine. The new generation film is able to be manufactured at a far higher rate than previously possible enabling the TabWrap system to be run at higher operating speeds. This has resulted in a significant decrease in the operating costs of the TabWrap system making it more competitive within the marketplace.

Richard Trevillion, Chief Executive Officer, BioProgress said:

"It has been a very exciting and productive year for the Company. The relationship with Merck-Serono announced today is further validation and a fantastic endorsement of BioProgresss valuable technology. BioProgress has come a long way from concept to fully validated commercial products that earn revenue. The dedicated team at BioProgress has worked extremely hard and can be proud of its achievements and we look forward to a highly successful year ahead and the further enhancement of shareholder value.

Steve Martin, Chief Development Officer, BioProgress, said:

We are working with more partners than we ever have done in the past across a range of technologies. Along with our own product development program, we will see a number of innovative product launches including some significant partner brands.

For further information:



BioProgress Plc
+ 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO





Buchanan Communications
+ 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court



About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Companys filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.

BioProgress says trading above annualised turnover expectations in H1
AFX


LONDON (Thomson Financial) - Speciality drug company BioProgress PLC said it is trading above annualised turnover expectations for the half year to June 2007 and that it is confident of maintaining its first-half progress through the second half.

BioProgress said it has struck a commercial relationship with Merck Serono for female healthcare products and that it is in detailed product and technology discussions with over 15 different pharmaceutical companies for commercial partnering arrangements.

Additionally, the company said it has identified its preferred partner for its quitting smoking product, DBP121. It is assessing the marketing aspects of the partnering programme on a global basis, with BioProgress retaining certain rights to some territories and the manufacturing rights.

BioProgress added that it is launching a new topical treatment for cellulite and said that it looks forward to a highly successful year.

TFN.newsdesk@thomson.com

Can't see the magic word "profit". It's all a bit turnover-ish, Fred. ;-))

BA,Agreed but for still a young company it is taking the right steps and projected figures 12/07 "hopes" shows profit out of rising double turnover. These figures base on reports before information to-day.

DYOH, but I am holding quite a few and will do so for the longterm.

Fred - no doubt they're getting there. Happy to watch here ................ and occasionally take the mickey! ;-)))

In my opinion, for what's worth...now is the time to buy BPRG....I've never been in it before but things look promising to me and I think that BPRG may well make me lots of profit...hopefully like SEO (l (6 x my money and I stayed out of the bad bit) but BPRG is round the other way...ie; they've had their bad bit and now the good times are gonna roll.
All IMHO dyor etc
Di
:-)